Inovio Pharmaceuticals Inc - חוב כולל להון INO

This price chart helps assess the resources of Inovio Pharmaceuticals (INO) for implementing the Cellectra platform and submitting FDA applications for the drug INO-3107. The debt-to-equity ratio stands at 1.74, highlighting a liquidity shortage driven by a lack of sales and R&D expenditures. Meanwhile, the DNA vaccine developer is implementing energy-saving equipment and optimizing logistics to minimize environmental impact.

Analyzing the financing structure is critical to separating the fundamental stability of Inovio Pharmaceuticals (INO) from market noise. This metric compares total liabilities to equity, determining the business's degree of dependence on external borrowings. By analyzing the debt-to-equity chart, an investor assesses financial leverage and default risk. A low debt load ensures security during the transition to the commercialization of DNA drugs, creating a foundation for generating a stable cash flow.